Jeffrey M. Leiden
2014 - Vertex Pharmaceuticals
In 2014, Jeffrey M. Leiden earned a total compensation of $36.6M as Chairman, President & CEO at Vertex Pharmaceuticals, a 179% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $2,970,000 |
|---|---|
| Option Awards | $12,669,261 |
| Salary | $1,100,000 |
| Stock Awards | $19,883,350 |
| Other | $12,857 |
| Total | $36,635,468 |
Leiden received $19.9M in stock awards, accounting for 54% of the total pay in 2014.
Leiden also received $3M in non-equity incentive plan, $12.7M in option awards, $1.1M in salary and $12.9K in other compensation.
Rankings
In 2014, Jeffrey M. Leiden's compensation ranked 34th out of 13,032 executives tracked by ExecPay. In other words, Leiden earned more than 99.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 34 out of 13,032 | 100th |
Division Manufacturing | 9 out of 4,967 | 100th |
Major group Chemicals And Allied Products | 3 out of 1,690 | 100th |
Industry group Drugs | 3 out of 1,369 | 100th |
Industry Pharmaceutical Preparations | 3 out of 1,042 | 100th |
Source: SEC filing on April 28, 2017.
Leiden's colleagues
We found four more compensation records of executives who worked with Jeffrey M. Leiden at Vertex Pharmaceuticals in 2014.